SPRING SCHOOL PROGRAMME
Check the programme regularly for updates
Tuesday 28 March
15:00-16:30
Registration
16.30-19.00
Workshops (40 students per workshop)
16:30-19:00
Workshop 1: Form your own opinion – how to judge a scientific publication
Hildegard Büning, ESGCT Education & Training
Els Verhoeyen, President, SFTCG, Board Member, ESGCT
16:30-19:00
Workshop 2: How to write a scientific manuscript
Leszek Lisowski - University of Sydney
Thomas Gallagher - Human Gene Therapy
​
16:30-19:00
Workshop 3: Ethical consideration in experimental, pre-clinical and clinical gene therapy
Frank Staal, University of Leiden
​
​
19:30
Dinner
Wednesday 29 March
08:30-09:00
Welcome Address
Juan Bueren (President, ESGCT)
Els Verhoeyen (President, SFTCG, Board Member, ESGCT)
Hildegard Büning (ESGCT Education & Training)
​
09:00-10:00
Keynote
INV01: Juan Bueren, Ciemat Madrid
Moving from Concept to Clinical Reality – 33 years from the first human clinical trial to now
​
10:00-11:20
Session 1: Gene therapy tools - insights by experts (LV)
INV02: Axel Schambach, Hannover Medical School
What you should know about retro/lentiviral vector design
INV03: Els Verhoeyen, University of Nice
How to improve nature – the next generation of lentiviral vectors
11:20-11:50
Coffee Break
11:50-12:50
Keynote
INV04: Frank Staal, Leiden University
Developing stem cell based gene therapy for Recombinase deficiencies
12:50-13:50
Lunch
13:50-15:00
Team building activity
15:00-16:20
Session 2:
Gene therapy tools - insights by experts (AAV)
INV05: Hildegard Büning, Hannover Medical School
Almost a virus – the adeno-associated virus (AAV) vector system
INV06: Leszek Lesowski, University of Sydney
How to improve nature – the next generation of AAV vectors
​
16:20-17:20
Keynote
INV07: Gloria Gonzalez-Aseguinolaza, FIMA Pamplona
Liver-directed Gene Therapy – the long journey to the market
​
17:20-17:50
Coffee Break
17:50-19:10
Session 3: Gene therapy tools - insights by experts (non-viral vectors)
INV08: Pieter Vader, University Medical Center Utrecht
Extracellular vesicles
INV09: Tristan Montier, University of Brest
Fine-tuning of nanoparticles for aerosol gene transfer: applications to cystic fibrosis
19:30
Dinner
20:30 After dinner keynote
INV10: Nathalie Cartier, AskBio, Paris
Gene Therapy for neurodegenerative diseases from genetic to complex diseases : delivery and targets
Thursday 30 March
09:00-10:00
Keynote
INV11: Toni Cathomen, University Hospital Freiburg
Risk assessment of gene editing associated off-target effects
​
10:00-11:20
Session 4: Gene Therapy 2.0 – The Age of precision Gene Therapy
INV12: Paula Rio, Ciemat Madrid
Gene editing is coming to life as treatment strategy in Fanconi anemia
INV13: Matthias Titeux, Institut Imagine, Paris
Gene editing strategies for rare skin disorders
11:20-11:50
Coffee Break
11:50 -12:50
Keynote
INV14: Anne Galy, Genethon, Evry
The immune system does not like it to be tricked
​
12:50-13:50
Lunch
13:50-15:00
Team building activity
15:00-16:20
Session 5: The payload
INV15: Zoltan Ivics, Paul Ehrlich Institute, Langen
Wide awake and ready to move: non-viral genome engineering with Sleeping Beauty transposon vectors
INV14: Ivana Trapani, Tigem Naples
How to deliver large genomes in a too small vehicle
​
16:20 -17:20
Keynote
INV16: Vincenzo Cerullo, University of Helsinki
Dressing viruses in tumor’s clothing – new strategies in anti-tumor therapy
17:20-17:50
Coffee Break
17:50-19:10
Session 6: Fighting cancer with novel weapons
INV17: Andrea Schmidts, Technical University of Munich
CAR-T cells – how to make a living drug
INV18: Eliana Ruggiero, HSR, Milan
The world beyond CAR T cells
19:30
Dinner
Friday 31 March
09.00-10.00
Keynote
INV19 Alberto Auricchio, Tigem Naples
Vision – Gene Therapy for fighting blindness
10.00-10.30
Coffee Break
10:30-11.50
Session 7: Pre-clinical and clinical gene therapy
INV20: Giuliana Ferrari, SR Tiget, Milan
Gene therapy for hemoglobinopathies: past, present and future
INV21: Alessandro Aiuti, HSR Tiget, Milan
Gene Therapy for primary immunodeficiencies, the prime target for lentiviral vector ex vivo gene therapy, is reaching its next level
​
11:50-12.50
Keynote
INV22: Claire Booth, UCLondon
It is all about accessibility
​
12:50
Closing
​
Juan Bueren, Hildegard Büning & Els Verhoeyen